Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It is developing multiple precision-targeted products based on their manocept platform to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. The company operates through the following segments: Diagnostics, Therapeutics and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.
Market Cap | 22.163 Million | Shares Outstanding | 30.36 Million | Avg 30-day Volume | 40.277 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.19 |
Price to Revenue | 58.8172 | Debt to Equity | -0.054 | EBITDA | -11.686 Million |
Price to Book Value | 0.0 | Operating Margin | -2871.6585 | Enterprise Value | 23.174 Million |
Current Ratio | 0.474 | EPS Growth | 0.071 | Quick Ratio | 0.248 |
1 Yr BETA | 0.2142 | 52-week High/Low | 1.96 / 0.56 | Profit Margin | -2881.7988 |
Operating Cash Flow Growth | 5.5739 | Altman Z-Score | -154.2413 | Free Cash Flow to Firm | -4.887 Million |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
53,977 | 2022-05-31 | 9 | |
|
8,109,294 | 2022-05-31 | 7 | |
|
151,388 | 2022-05-31 | 10 | |
|
58,068 | 2022-05-31 | 8 | |
ROSOL MICHAEL STANLEY CHIEF MEDICAL OFFICER |
|
21,391 | 2022-01-14 | 3 |
|
33,425 | 2021-11-15 | 2 | |
|
33,600 | 2021-11-15 | 2 | |
MIKHAIL MICHEL CHIEF REGULATORY OFFICER |
|
75,000 | 2021-11-15 | 2 |
|
16,519 | 2021-06-30 | 0 | |
|
18,242 | 2021-06-30 | 0 | |
LATKIN JED CEO, COO & CFO |
|
10,600 | 2021-02-15 | 0 |
KAUFMAN JOEL H. CHIEF BUSINESS OFFICER |
|
9,648 | 2021-02-15 | 0 |
|
12,500 | 2021-01-13 | 0 | |
|
10,000 | 2021-01-13 | 0 | |
COPE FREDERICK O SVP & CSO |
|
585,052 | 2018-06-29 | 0 |
|
341,446 | 2018-02-20 | 0 | |
|
157,244 | 2018-02-20 | 0 | |
|
78,000 | 2017-06-30 | 0 | |
REGAN WILLIAM J. SVP & CCO |
|
172,977 | 2017-06-29 | 0 |
GOLDBERG MICHAEL M PRESIDENT & CEO |
|
5,921,023 | 2017-05-16 | 0 |
KLIMA THOMAS J SVP & CHIEF COMMERCIAL OFFICER |
|
51,935 | 2017-02-06 | 0 |
|
No longer subject to file | 2016-04-20 | 0 | |
LARSON BRENT L EVP, CFO, TREAS & SEC'Y |
|
0 | 2016-02-25 | 0 |
|
38,918 | 2016-01-06 | 0 | |
|
239,950 | 2015-07-31 | 0 | |
|
No longer subject to file | 2015-07-16 | 0 | |
|
No longer subject to file | 2015-07-16 | 0 | |
TOMBLYN MICHAEL SVP, CHIEF MED. OFFICER |
|
100,000 | 2015-07-02 | 0 |
TULIP THOMAS H. CHIEF BUS. OFFICER |
|
77,966 | 2015-03-26 | 0 |
GONZALEZ RICARDO J CHIEF EXECUTIVE OFFICER |
|
0 | 2014-10-13 | 0 |
PLATINUM LIQUID OPPORTUNITY MANAGEMENT (NY) LLC PLATINUM PARTNERS LIQUID OPPORTUNITY MASTER FUND L.P. |
|
No longer subject to file | 2014-09-02 | 0 |
PLATINUM PARTNERS VALUE ARBITRAGE FUND, LP |
|
15,106,431 | 2014-08-12 | 0 |
|
318,505 | 2014-06-01 | 0 | |
REININGER CORNELIA SVP & CHIEF MEDICAL OFFICER |
|
0 | 2014-01-28 | 0 |
|
10,073,375 | 2013-11-13 | 0 | |
BROWN RODGER A VICE PRESIDENT |
|
123,027 | 2013-03-13 | 0 |
|
29,250 | 2013-02-21 | 0 | |
|
2,843,130 | 2011-11-17 | 0 | |
|
158,620 | 2011-05-27 | 0 | |
BLAIR ANTHONY K VP-MANUFACTURING & OPERATIONS |
|
38,544 | 2011-05-27 | 0 |
RASH DOUGLAS L VICE PRESIDENT, MARKETING |
|
0 | 2010-12-21 | 0 |
|
70,000 | 2010-12-08 | 0 | |
|
141,000 | 2010-06-16 | 0 | |
|
289,256 | 2010-03-16 | 0 | |
|
61,500 | 2009-12-30 | 0 | |
|
0 | 2009-01-05 | 0 | |
BOSCH CARL M VP - INSTRUMENT DEVELOPMENT |
|
50,000 | 2006-12-15 | 0 |
|
20,000 | 2006-12-15 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2022-06-01 16:33:30 -0400 | 2022-05-31 | A | 2,500 | a | 53,977 | direct | -3.125 | -15.625 | 0.0 | 1 | -15.625 | 6 | ||||
2022-06-01 16:37:05 -0400 | 2022-05-31 | A | 2,500 | a | 151,388 | direct | -3.125 | -15.625 | 0.0 | 1 | -15.625 | 6 | ||||
2022-06-01 16:35:21 -0400 | 2022-05-31 | A | 2,500 | a | 8,095,895 | direct | -3.125 | -15.625 | 0.0 | 1 | -15.625 | 6 | ||||
2022-06-01 16:32:14 -0400 | 2022-05-31 | A | 2,500 | a | 58,068 | direct | -3.125 | -15.625 | 0.0 | 1 | -15.625 | 6 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
NAVIDEA BIOPHARMACEUTICALS I NAVB | 2022-06-30 22:15:03 UTC | -8.1501 | 9.7201 | 200000 |
NAVIDEA BIOPHARMACEUTICALS I NAVB | 2022-06-30 21:45:03 UTC | -8.1501 | 9.7201 | 200000 |
NAVIDEA BIOPHARMACEUTICALS I NAVB | 2022-06-30 21:15:03 UTC | -8.1501 | 9.7201 | 200000 |
NAVIDEA BIOPHARMACEUTICALS I NAVB | 2022-06-30 20:45:03 UTC | -8.1501 | 9.7201 | 200000 |
NAVIDEA BIOPHARMACEUTICALS I NAVB | 2022-06-30 20:15:04 UTC | -8.1501 | 9.7201 | 200000 |
NAVIDEA BIOPHARMACEUTICALS I NAVB | 2022-06-30 19:45:03 UTC | -8.1501 | 9.7201 | 200000 |
NAVIDEA BIOPHARMACEUTICALS I NAVB | 2022-06-30 19:15:03 UTC | -8.1501 | 9.7201 | 200000 |
NAVIDEA BIOPHARMACEUTICALS I NAVB | 2022-06-30 18:45:04 UTC | -8.1501 | 9.7201 | 200000 |
NAVIDEA BIOPHARMACEUTICALS I NAVB | 2022-06-30 18:15:04 UTC | -8.1501 | 9.7201 | 200000 |
NAVIDEA BIOPHARMACEUTICALS I NAVB | 2022-06-30 17:45:03 UTC | -8.1501 | 9.7201 | 200000 |
NAVIDEA BIOPHARMACEUTICALS I NAVB | 2022-06-30 17:15:03 UTC | -8.1501 | 9.7201 | 200000 |
NAVIDEA BIOPHARMACEUTICALS I NAVB | 2022-06-30 16:45:04 UTC | -8.1501 | 9.7201 | 200000 |
NAVIDEA BIOPHARMACEUTICALS I NAVB | 2022-06-30 16:15:03 UTC | -8.1501 | 9.7201 | 200000 |
NAVIDEA BIOPHARMACEUTICALS I NAVB | 2022-06-30 15:45:03 UTC | -8.1501 | 9.7201 | 200000 |
NAVIDEA BIOPHARMACEUTICALS I NAVB | 2022-06-30 15:15:03 UTC | -8.1501 | 9.7201 | 200000 |
NAVIDEA BIOPHARMACEUTICALS I NAVB | 2022-06-30 14:45:03 UTC | -8.1501 | 9.7201 | 200000 |
NAVIDEA BIOPHARMACEUTICALS I NAVB | 2022-06-30 14:15:03 UTC | -8.1501 | 9.7201 | 200000 |
NAVIDEA BIOPHARMACEUTICALS I NAVB | 2022-06-30 13:45:03 UTC | -8.3144 | 9.8844 | 200000 |
NAVIDEA BIOPHARMACEUTICALS I NAVB | 2022-06-30 13:15:03 UTC | -8.3144 | 9.8844 | 200000 |
NAVIDEA BIOPHARMACEUTICALS I NAVB | 2022-06-30 12:45:03 UTC | -8.3144 | 9.8844 | 200000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|